InnoSer
InnoSer Laboratories is a company dedicated to discovery, preclinical, and clinical research services, supporting drug development with tailored strategies, transparent pricing, and a commitment to the 3Rs principles of Replacement, Reduction, and Refinement in animal testing. They offer a wide range of services across various therapeutic areas including neurology, oncology, immunology, nephrology, and more, with a focus on responsible animal care and innovative research solutions.
Industries
Nr. of Employees
small (1-50)
InnoSer
Diepenbeek, Limburg, Belgium, Europe
Services
Breeding, genotyping, health monitoring (FELASA-based), sanitation via embryo transfer, and long-term storage of rodent lines via embryo and sperm cryopreservation to maintain research-ready animal supplies.
One-night automated discrimination learning and other home-cage behavioral protocols using video monitoring and automated data analysis to assess cognitive and behavioral endpoints with reduced handling.
Integrated in vitro and in vivo screening to advance hit compounds into lead optimization using multi-parametric potency, selectivity and early ADME profiling.
ADME/PK profiling, metabolic stability, dose-range finding, MTD determination and in vivo efficacy testing to refine lead compounds prior to preclinical development.
Late-stage preclinical studies in rodents including safety pharmacology, single and repeated dose toxicology, toxicokinetics and support for IND-enabling dossiers; processes to support GLP accreditation.
Custom assay development, organoid and PDX model generation/characterization, biomarker ID/validation, flow cytometry and high-content imaging to evaluate target druggability and translational potential; includes biobanking.
Breeding, genotyping, health monitoring (FELASA-based), sanitation via embryo transfer, and long-term storage of rodent lines via embryo and sperm cryopreservation to maintain research-ready animal supplies.
One-night automated discrimination learning and other home-cage behavioral protocols using video monitoring and automated data analysis to assess cognitive and behavioral endpoints with reduced handling.
Integrated in vitro and in vivo screening to advance hit compounds into lead optimization using multi-parametric potency, selectivity and early ADME profiling.
ADME/PK profiling, metabolic stability, dose-range finding, MTD determination and in vivo efficacy testing to refine lead compounds prior to preclinical development.
Late-stage preclinical studies in rodents including safety pharmacology, single and repeated dose toxicology, toxicokinetics and support for IND-enabling dossiers; processes to support GLP accreditation.
Custom assay development, organoid and PDX model generation/characterization, biomarker ID/validation, flow cytometry and high-content imaging to evaluate target druggability and translational potential; includes biobanking.
Expertise Areas
- Preclinical CRO services
- Translational rodent disease modeling
- Target validation and custom assay development
- Hit-to-lead and lead optimization workflows
Key Technologies
- Organoid culture and patient-derived organoids (PDO)
- Patient-derived xenografts (PDX)
- Microphysiological systems / organ-on-chip (MPS / OoC)
- Microfluidics
News & Updates
Together, CureSHANK, a nonprofit research foundation, and InnoSer, preclinical research CRO, aim to remove barriers to drug development for Phelan-McDermid syndrome treatment by providing the global research community with accessible and industry-standard preclinical testing services.
In collaboration with Professor Ype, InnoSer introduces a new preclinical research model for Angelman Syndrome to support the development of new therapeutics for rare genetic neurological diseases.
InnoSer will serve as the central hub for Kabuki Syndrome Foundation-funded preclinical research in the Kmt2d+/βGeo mouse model, aiming to inform clinical trial readiness.
InnoSer will participate in the ADPD 2025 conference, showcasing new data on neurodegenerative disease models.
Details about the partnership to provide accessible preclinical testing services for PMS treatments.
Introduction of a new mouse model for Angelman Syndrome to support therapeutic development.
Together, CureSHANK, a nonprofit research foundation, and InnoSer, preclinical research CRO, aim to remove barriers to drug development for Phelan-McDermid syndrome treatment by providing the global research community with accessible and industry-standard preclinical testing services.
In collaboration with Professor Ype, InnoSer introduces a new preclinical research model for Angelman Syndrome to support the development of new therapeutics for rare genetic neurological diseases.
InnoSer will serve as the central hub for Kabuki Syndrome Foundation-funded preclinical research in the Kmt2d+/βGeo mouse model, aiming to inform clinical trial readiness.
InnoSer will participate in the ADPD 2025 conference, showcasing new data on neurodegenerative disease models.
Details about the partnership to provide accessible preclinical testing services for PMS treatments.
Introduction of a new mouse model for Angelman Syndrome to support therapeutic development.